Comparability study of Rituximab originator and follow-on biopharmaceutical
- 1 June 2017
- journal article
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 140, 239-251
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Physicochemical and Functional Comparability Between the Proposed Biosimilar Rituximab GP2013 and Originator RituximabBioDrugs, 2013
- Development and validation of an antibody-dependent cell-mediated cytotoxicity-reporter gene assaymAbs, 2012
- An innovative approach for the characterization of the isoforms of a monoclonal antibody productmAbs, 2011
- Worldwide experience with biosimilar developmentmAbs, 2011
- Comparability assessments of process and product changes made during development of two different monoclonal antibodiesBiologicals, 2011
- Post-translational Modifications Differentially Affect IgG1 Conformation and Receptor BindingMolecular & Cellular Proteomics, 2010
- Enhanced antibody half-life improves in vivo activityNature Biotechnology, 2010
- Impact of Glycosylation on Effector Functions of Therapeutic IgGPharmaceuticals, 2010
- Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistanceOncogene, 2003
- Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular ToxicityJournal of Biological Chemistry, 2002